Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Phase of Trial: Phase II/III
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Proof of concept; Therapeutic Use
- Sponsors Rhythm
- 31 Oct 2017 Preliminary results from 5 patients with Bardet-Biedl syndrome (BBS) presented in a Rhythm Pharmaceuticals media release.
- 31 Oct 2017 According to a Rhythm Pharmaceuticals media release, preliminary results (n = 5) from this trial have been presented at ObesityWeek 2017 Meeting.
- 14 Apr 2017 Status changed from not yet recruiting to recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History